Guardant Health to Report Third Quarter 2022 Financial Results on November 3, 2022
10/10/2022 - 04:05 PM
PALO ALTO, Calif. --(BUSINESS WIRE)--
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2022 after market close on Thursday, November 3, 2022 . Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time .
Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com . The webcast will be archived and available for replay after the event.
About Guardant Health
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the Shield™ test, aims to address the needs of individuals eligible for cancer screening. For more information, visit guardanthealth.com and follow the company on LinkedIn and Twitter .
View source version on businesswire.com : https://www.businesswire.com/news/home/20221010005079/en/
Investor Contact:
Alex Kleban
investors@guardanthealth.com
+1 657-254-5417
Media Contact:
Michele Rest
press@guardanthealth.com
+1 215-910-2138
Source: Guardant Health, Inc.
Guardant Health Inc
NASDAQ:GH
GH Rankings
#4656 Ranked by Stock Gains
GH Stock Data
Industry
Dental Laboratories
Sector
Manufacturing
Tags
Health Services, Medical/Nursing Services, Manufacturing, Dental Laboratories
About GH
we believe conquering cancer is a big data problem. that’s why we built the world’s leading comprehensive liquid biopsy. this non-invasive tool for accessing and sequencing tumor dna is used by thousands of oncologists to help tens of thousands of advanced cancer patients. we believe the boom in cancer data acquisition we helped launch will drive important discoveries and new products. we’re working on some exciting ones, including in early detection, where the impact on patients can be profound. we’ve raised more than $500 million from investors including sequoia capital, khosla ventures, orbimed, and softbank.